Noah AI Industry News

Delivers real-time biopharma news and signals — powered by AI, curated for professionals.

Mark Cuban's Cost Plus Drugs to Partner with TrumpRx, Shaking Up Prescription Drug Landscape

Mark Cuban's Cost Plus Drugs to Partner with TrumpRx, Shaking Up Prescription Drug Landscape

In a significant development for the pharmaceutical industry, Mark Cuban announced that his online pharmacy, Cost Plus Drugs, will collaborate with TrumpRx, the upcoming direct-to-consumer prescription drug website initiated by President Donald Trump's administration. This partnership, revealed during Cuban's keynote address at the HLTH conference in Las Vegas, marks a notable shift in the landscape of prescription drug pricing and accessibility in the United States.

NoahAI News10/21/2025
Daiichi Sankyo and Merck's Ovarian Cancer ADC Advances to Phase 3 Trial After Promising Midphase Results

Daiichi Sankyo and Merck's Ovarian Cancer ADC Advances to Phase 3 Trial After Promising Midphase Results

Daiichi Sankyo and Merck & Co. have reported encouraging phase 2 data for their antibody-drug conjugate (ADC) raludotatug deruxtecan (R-DXd) in ovarian cancer, paving the way for the treatment's advancement to a pivotal phase 3 trial. The results, presented at the 2025 European Society for Medical Oncology (ESMO) Congress, demonstrate the potential of this CDH6-directed therapy in addressing the unmet needs of patients with recurrent, platinum-resistant ovarian, primary peritoneal, or fallopian tube cancers.

NoahAI News10/21/2025
AstraZeneca and Daiichi Sankyo's Datroway Shows Promise in Hard-to-Treat Breast Cancer

AstraZeneca and Daiichi Sankyo's Datroway Shows Promise in Hard-to-Treat Breast Cancer

AstraZeneca and Daiichi Sankyo have announced groundbreaking results from their Phase 3 TROPION-Breast02 trial, evaluating the efficacy of Datroway in patients with inoperable metastatic triple-negative breast cancer (TNBC). The study, presented at the European Society for Medical Oncology, demonstrated significant improvements in overall survival and progression-free survival compared to chemotherapy.

NoahAI News10/21/2025
CVS Health Ventures Leads $25M Investment in Knownwell to Scale Obesity Care Model

CVS Health Ventures Leads $25M Investment in Knownwell to Scale Obesity Care Model

In a significant move within the obesity care sector, knownwell, a weight-inclusive primary care and metabolic health company, has secured $25 million in fresh funding. This latest investment round, led by CVS Health Ventures, marks a pivotal moment in the company's growth trajectory and underscores the increasing focus on comprehensive obesity treatment models.

NoahAI News10/21/2025
Roche's Gazyva Secures FDA Approval for Lupus Nephritis, Expanding Beyond Oncology

Roche's Gazyva Secures FDA Approval for Lupus Nephritis, Expanding Beyond Oncology

Roche's long-standing oncology drug Gazyva (obinutuzumab) has received FDA approval for the treatment of adults with active lupus nephritis, marking a significant expansion of its therapeutic applications. This development comes as the lupus treatment landscape prepares for a potential shake-up, with Gazyva now positioned to compete in a market dominated by GSK's Benlysta.

NoahAI News10/21/2025
Summit's Dual-Acting Drug Shows Promise in Lung Cancer Trial

Summit's Dual-Acting Drug Shows Promise in Lung Cancer Trial

Summit Therapeutics and Akeso's dual-acting lung cancer drug ivonescimab has demonstrated significant efficacy in a closely watched trial, potentially reshaping first-line treatment regimens for non-small cell lung cancer (NSCLC). The Phase 3 HARMONi-6 trial, conducted in Chinese patients, showed that ivonescimab combined with chemotherapy substantially delayed disease progression compared to the immunotherapy Tevimbra and chemotherapy.

NoahAI News10/21/2025
Roche Pursues FDA Approval for Eye Disease Drug Despite Mixed Phase 3 Results

Roche Pursues FDA Approval for Eye Disease Drug Despite Mixed Phase 3 Results

Roche, the Swiss pharmaceutical giant, is moving forward with plans to seek regulatory approval for its eye disease drug candidate vamikibart, despite encountering mixed results in its recent phase 3 clinical trials. The company's pursuit of this potential treatment for uveitic macular edema (UME) highlights the complexities of drug development in the ophthalmology space and underscores the pharmaceutical industry's ongoing efforts to address unmet medical needs.

NoahAI News10/21/2025
Exelixis Shares Dip as Colorectal Cancer Trial Results Fall Short of Expectations

Exelixis Shares Dip as Colorectal Cancer Trial Results Fall Short of Expectations

Exelixis, a prominent biotechnology company, faced a setback on Monday as its shares dropped more than 10% following the release of results from a pivotal clinical trial. The STELLAR-303 study, which tested the experimental drug zanzalintinib in combination with Tecentriq for metastatic colorectal cancer, yielded results that left some investors and analysts underwhelmed.

NoahAI News10/21/2025
Ōura Pursues FDA Clearance for Blood Pressure Feature in Smart Ring

Ōura Pursues FDA Clearance for Blood Pressure Feature in Smart Ring

Ōura, the smart ring manufacturer, has announced its intention to seek Food and Drug Administration (FDA) clearance for a new blood pressure monitoring feature. This move signifies a notable step in the company's expansion into clinical applications, building upon its existing consumer health tracking capabilities.

NoahAI News10/21/2025
HistoSonics Secures $250M in Series D Funding, Accelerating Expansion of Innovative Cancer Treatment Platform

HistoSonics Secures $250M in Series D Funding, Accelerating Expansion of Innovative Cancer Treatment Platform

HistoSonics, a leading developer of non-invasive cancer treatments, has successfully raised $250 million in an oversubscribed Series D financing round. This substantial investment comes just two months after a syndicate of investors acquired a majority stake in the company, valuing it at $2.5 billion. The latest funding injection is set to fuel the commercial expansion of HistoSonics' groundbreaking Edison System, which utilizes advanced sonic beam technology to target and destroy tumors.

NoahAI News10/21/2025
Merck Unveils $3 Billion Manufacturing Expansion in Virginia, Part of $70 Billion U.S. Investment Plan

Merck Unveils $3 Billion Manufacturing Expansion in Virginia, Part of $70 Billion U.S. Investment Plan

Merck & Co. has announced the construction of a new $3 billion manufacturing facility at its Elkton, Virginia campus, marking a significant expansion of the company's U.S. operations. The investment is part of Merck's broader plan to allocate over $70 billion towards manufacturing, research and development, and capital projects across the United States.

NoahAI News10/21/2025
FarmboxRx Founder Joins HLM Investment Partners, Bringing Entrepreneurial Expertise to Healthcare Startups

FarmboxRx Founder Joins HLM Investment Partners, Bringing Entrepreneurial Expertise to Healthcare Startups

Ashley Tyrner-Dolce, the founder of FarmboxRx, has joined HLM Investment Partners as an operating partner, leveraging her experience in scaling a healthcare startup to mentor new founders. This move comes after the successful acquisition of FarmboxRx by Pyx Health for nearly $50 million in June, marking a significant milestone in the food-as-engagement sector of healthcare.

NoahAI News10/21/2025
«1...323334...67»